Oral pathogens exacerbate Parkinson's disease by promoting Th1 cell infiltration in mice
- PMID: 37978405
- PMCID: PMC10655362
- DOI: 10.1186/s40168-023-01685-w
Oral pathogens exacerbate Parkinson's disease by promoting Th1 cell infiltration in mice
Abstract
Background: Parkinson's disease (PD) is a common chronic neurological disorder with a high risk of disability and no cure. Periodontitis is an infectious bacterial disease occurring in periodontal supporting tissues. Studies have shown that periodontitis is closely related to PD. However, direct evidence of the effect of periodontitis on PD is lacking. Here, we demonstrated that ligature-induced periodontitis with application of subgingival plaque (LIP-SP) exacerbated motor dysfunction, microglial activation, and dopaminergic neuron loss in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice.
Results: The 16S rRNA gene sequencing revealed that LIP-SP induced oral and gut dysbiosis. Particularly, Veillonella parvula (V. parvula) and Streptococcus mutans (S. mutans) from oral ligatures were increased in the fecal samples of MPTP + LIP-SP treated mice. We further demonstrated that V. parvula and S. mutans played crucial roles in LIP-SP mediated exacerbation of motor dysfunction and neurodegeneration in PD mice. V. parvula and S. mutans caused microglial activation in the brain, as well as T helper 1 (Th1) cells infiltration in the brain, cervical lymph nodes, ileum and colon in PD mice. Moreover, we observed a protective effect of IFNγ neutralization on dopaminergic neurons in V. parvula- and S. mutans-treated PD mice.
Conclusions: Our study demonstrates that oral pathogens V. parvula and S. mutans necessitate the existence of periodontitis to exacerbate motor dysfunction and neurodegeneration in MPTP-induced PD mice. The underlying mechanisms include alterations of oral and gut microbiota, along with immune activation in both brain and peripheral regions. Video Abstract.
Keywords: Oral pathogens; Parkinson’s disease; Periodontitis; T helper 1 cells.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10655362/bin/40168_2023_1685_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10655362/bin/40168_2023_1685_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10655362/bin/40168_2023_1685_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10655362/bin/40168_2023_1685_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10655362/bin/40168_2023_1685_Fig5_HTML.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10655362/bin/40168_2023_1685_Fig6_HTML.gif)
Similar articles
-
Dopamine receptor D2 on CD4+ T cells is protective against neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.Brain Behav Immun. 2021 Nov;98:110-121. doi: 10.1016/j.bbi.2021.08.220. Epub 2021 Aug 14. Brain Behav Immun. 2021. PMID: 34403737
-
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.Front Cell Infect Microbiol. 2022 Aug 10;12:887407. doi: 10.3389/fcimb.2022.887407. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36034698 Free PMC article.
-
N-acetyl-L-leucine protects MPTP-treated Parkinson's disease mouse models by suppressing Desulfobacterota via the gut-brain axis.Brain Res Bull. 2023 Oct 1;202:110729. doi: 10.1016/j.brainresbull.2023.110729. Epub 2023 Aug 12. Brain Res Bull. 2023. PMID: 37579888
-
The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.Curr Pharm Des. 2011;17(5):489-507. doi: 10.2174/138161211795164095. Curr Pharm Des. 2011. PMID: 21375482 Review.
-
alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.CNS Neurol Disord Drug Targets. 2010 Aug;9(4):482-90. doi: 10.2174/187152710791556177. CNS Neurol Disord Drug Targets. 2010. PMID: 20522009 Review.
Cited by
-
Differentiation and regulation of CD4+ T cell subsets in Parkinson's disease.Cell Mol Life Sci. 2024 Aug 17;81(1):352. doi: 10.1007/s00018-024-05402-0. Cell Mol Life Sci. 2024. PMID: 39153043 Free PMC article. Review.
-
Gut Microbiota-Induced Modulation of the Central Nervous System Function in Parkinson's Disease Through the Gut-Brain Axis and Short-Chain Fatty Acids.Mol Neurobiol. 2024 Aug 12. doi: 10.1007/s12035-024-04370-7. Online ahead of print. Mol Neurobiol. 2024. PMID: 39134825
-
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside.Transl Neurodegener. 2024 Feb 27;13(1):12. doi: 10.1186/s40035-024-00404-1. Transl Neurodegener. 2024. PMID: 38414054 Free PMC article. Review.
-
Exploring the causal relationship between B lymphocytes and Parkinson's disease: a bidirectional, two-sample Mendelian randomization study.Sci Rep. 2024 Feb 2;14(1):2783. doi: 10.1038/s41598-024-53287-7. Sci Rep. 2024. PMID: 38307922 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 81991503/National Natural Science Foundation of China
- 19MC1910600/Shanghai Clinical Research Center for Oral Diseases
- 19MC1910600/Shanghai Clinical Research Center for Oral Diseases
- 19MC1910600/Shanghai Clinical Research Center for Oral Diseases
- 19MC1910600/Shanghai Clinical Research Center for Oral Diseases
- 19MC1910600/Shanghai Clinical Research Center for Oral Diseases
- 19MC1910600/Shanghai Clinical Research Center for Oral Diseases
- 19MC1910600/Shanghai Clinical Research Center for Oral Diseases
- 19MC1910600/Shanghai Clinical Research Center for Oral Diseases
- shslczdzk01601/Shanghai Municipal Key Clinical Specialty
- shslczdzk01601/Shanghai Municipal Key Clinical Specialty
- shslczdzk01601/Shanghai Municipal Key Clinical Specialty
- shslczdzk01601/Shanghai Municipal Key Clinical Specialty
- shslczdzk01601/Shanghai Municipal Key Clinical Specialty
- 2022ZZ01017/Shanghai's Top Priority Research Center
- 2022ZZ01017/Shanghai's Top Priority Research Center
- 2022ZZ01017/Shanghai's Top Priority Research Center
- 2022ZZ01017/Shanghai's Top Priority Research Center
- SHSMU-ZDCX20212500/The innovative research team of high-level local universities in Shanghai
- SHSMU-ZDCX20212500/The innovative research team of high-level local universities in Shanghai
- SHSMU-ZDCX20212500/The innovative research team of high-level local universities in Shanghai
- SHSMU-ZDCX20212500/The innovative research team of high-level local universities in Shanghai
- SHSMU-ZDCX20212500/The innovative research team of high-level local universities in Shanghai
- SHSMU-ZDCX20212500/The innovative research team of high-level local universities in Shanghai
- KQYJXK2021/The research discipline fund from Ninth People's Hospital
- KQYJXK2021/The research discipline fund from Ninth People's Hospital
- KQYJXK2021/The research discipline fund from Ninth People's Hospital
- KQYJXK2021/The research discipline fund from Ninth People's Hospital
- KQYJXK2021/The research discipline fund from Ninth People's Hospital
LinkOut - more resources
Full Text Sources
Medical